PubMed Health⌕ Search

PubMed · 15566866

Viral diagnosis by antigen detection techniques.

Abstract

BACKGROUND: Diagnosis of viral infections can be obtained in the early stages of a disease by detection of viral antigens directly in the clinical specimen. This has become an important tool for rapid virus diagnosis. METHODS: Antigens produced during virus infections can be detected either in cells collected from the site of infection by immunohistological investigation or in secretions and blood by solid phase immunoassays (IA). Viruses causing acute respiratory infections can be diagnosed in cells from the respiratory tract, viruses causing vesicular eruptions in epithelial cells from skin scrapings, rabies virus in nerve cells of the brain or epithelial cells from skin and cornea and cytomegalovirus (CMV) matrix antigen, pp65, can be detected in peripheral blood leukocytes (PBL) by immunofluorescence (IF) or immunoperoxidase techniques. The quality of specimens can be easily checked during the reading of results. Some IAs for antigen detection, such as detection of HBsAg and HIV p24 antigen in blood are standardized and sensitive. Others give less sensitive results because of the variation of quality of the clinical specimen. The latex agglutination tests are mainly used for rapid detection of virus or viral antigens in faeces: rota-and adenoviruses; the method may not be very sensitive but yields a result within a few minutes. Assays detecting viral nucleic acids are more sensitive than antigen detection tests because of a tremendous amplification of gene segments obtained by the polymerase chain reaction (PCR). So far such assays are time consuming and expensive and are mainly used in specific clinical situations. RESULTS: After introduction of specific monoclonal antibodies (Mabs), the antigen detection techniques are increasingly used. the need for quality control, trained staff, and standardized reagents and methods for specimen collection and preparation is now being appreciated. IF for viral respiratory viruses is used for diagnosis and epidemiological studies all over the world. Likewise, IF is still the method most often used for rabies diagnosis. For CMV, the pp65 matrix antigen is shown to be a sensitive marker closely correlated with clinical symptoms. Its detection by the IF technique has proven to be superior to other techniques for prediction of CMV pneumonia in bone marrow transplant patients. IAs are currently used in fully automated systems for large scale diagnosis based on antigen detection in serum specimens. Increase of antibody specificity on the solid phase by use of Mabs directed against the most abundant viral antigen in the clinical specimen shortens the reaction time; this has been employed in most of the constantly appearing new rapid diagnosis kits based on the immunoassay principle. CONCLUSION: Although, in virology, more sensitive results are obtained by the gene detection method, PCR, directly in clinical samples, viral antigen detection tests are, after the introduction of Mabs for diagnostic purposes, increasingly used because of their low demand on laboratory equipment, their rapid and early result and relatively low cost. Antigen detection is successfully used directly in clinical specimens for rapid diagnosis of many viral infections as well as for identification of tissue culture isolated viruses. With Mab-based IAs the reaction time is shortened and new rapid, almost 'instant test' kits are appearing on the market.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Grandien. 1996. Viral diagnosis by antigen detection techniques.. https://doi.org/10.1016/0928-0197(96)00209-7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗